What is the recommended infliximab dosing schedule for ankylosing spondylitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Infliximab Dosing Schedule for Ankylosing Spondylitis

For ankylosing spondylitis, infliximab should be administered at 5 mg/kg intravenously at weeks 0,2, and 6, followed by maintenance dosing every 6-8 weeks. This is the FDA-approved regimen and is supported by the highest quality evidence 1.

Standard Dosing Regimen

The established protocol consists of:

  • Induction phase: 5 mg/kg IV at weeks 0,2, and 6
  • Maintenance phase: 5 mg/kg IV every 6-8 weeks thereafter 1, 2

This dosing schedule has demonstrated robust efficacy, with approximately 60% of patients achieving ASAS20 response by week 24, with clinical benefit observable as early as week 2 3. The response is maintained with continued regular infusions 4.

Dose and Interval Adjustments

If patients have inadequate response or lose response over time, the dose can be increased up to 10 mg/kg or the interval shortened to as frequently as every 4 weeks 1, 2. However, be aware that higher doses carry increased risk of serious infections 1.

Real-world evidence suggests that dose and interval modifications are common and can improve clinical outcomes. In one Korean study, approximately 54% of patients had treatment pattern changes (dose or interval adjustments), and these patients showed greater improvements in disease activity scores compared to those without modifications 5. Drug survival was not negatively impacted by these adjustments 5.

Important Clinical Considerations

Patients who do not respond by week 14 are unlikely to respond with continued dosing and should have treatment discontinued 1. This is a critical decision point to avoid unnecessary exposure to a costly medication with potential adverse effects.

Monitoring Requirements

Before initiating and periodically during therapy 1:

  • Tuberculosis screening (PPD or interferon gamma release assay) is mandatory
  • Baseline: CBC, liver function tests, hepatitis profile
  • Ongoing: Periodic history and physical examination, consider yearly PPD, periodic CBC and LFTs

Infusion Administration

  • Infusions should be given over 2-3 hours 6
  • Premedication with antihistamines, acetaminophen, and/or corticosteroids may be considered to reduce infusion reactions 1
  • Approximately 20% of patients experience infusion reactions 1
  • Have appropriate personnel and medications available to treat anaphylaxis

Combination Therapy Considerations

Concomitant methotrexate is not required for ankylosing spondylitis (unlike rheumatoid arthritis where it is recommended) 1. However, some clinicians use low-dose methotrexate to reduce antibody formation against infliximab, which can lead to loss of efficacy 6, 7.

Comparative Efficacy

Among TNF inhibitors, indirect comparison suggests that infliximab 5 mg/kg at the standard induction schedule may be the most efficacious therapy for AS 8. Notably, a 3 mg/kg dose showed inferior efficacy and should not be used 8, 9.

Duration of Effect

Withdrawal of long-term therapy typically leads to disease flares within weeks to months, though rare cases of lasting remission have been reported 10. Continuous therapy is generally required to maintain disease control 4.

Contraindications

Infliximab at doses ≥5 mg/kg should not be given to patients with New York Heart Association functional class III or IV congestive heart failure 6.

References

Research

Infliximab in the treatment of ankylosing spondylitis.

Biologics : targets & therapy, 2007

Research

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

Expert review of clinical immunology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.